TWI895290B - 化合物的鹽及其晶型 - Google Patents

化合物的鹽及其晶型

Info

Publication number
TWI895290B
TWI895290B TW109135330A TW109135330A TWI895290B TW I895290 B TWI895290 B TW I895290B TW 109135330 A TW109135330 A TW 109135330A TW 109135330 A TW109135330 A TW 109135330A TW I895290 B TWI895290 B TW I895290B
Authority
TW
Taiwan
Prior art keywords
cancer
salt
formula
iii
water
Prior art date
Application number
TW109135330A
Other languages
English (en)
Chinese (zh)
Other versions
TW202128669A (zh
Inventor
李文姬
馮玲
Original Assignee
大陸商和記黃埔醫藥（上海）有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商和記黃埔醫藥（上海）有限公司 filed Critical 大陸商和記黃埔醫藥（上海）有限公司
Publication of TW202128669A publication Critical patent/TW202128669A/zh
Application granted granted Critical
Publication of TWI895290B publication Critical patent/TWI895290B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
    • C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW109135330A 2019-10-14 2020-10-13 化合物的鹽及其晶型 TWI895290B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910973785 2019-10-14
CN201910973785.3 2019-10-14

Publications (2)

Publication Number Publication Date
TW202128669A TW202128669A (zh) 2021-08-01
TWI895290B true TWI895290B (zh) 2025-09-01

Family

ID=75537486

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109135330A TWI895290B (zh) 2019-10-14 2020-10-13 化合物的鹽及其晶型

Country Status (14)

Country Link
US (1) US12559472B2 (https=)
EP (1) EP4045484A4 (https=)
JP (2) JP2022552329A (https=)
KR (1) KR20220088712A (https=)
CN (3) CN119751422A (https=)
AR (1) AR120202A1 (https=)
AU (1) AU2020367905A1 (https=)
BR (1) BR112022007035A2 (https=)
CA (1) CA3154064A1 (https=)
IL (1) IL292206B2 (https=)
MX (1) MX2022004274A (https=)
TW (1) TWI895290B (https=)
UA (1) UA129777C2 (https=)
WO (1) WO2021073494A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7736357B2 (ja) * 2021-12-13 2025-09-09 アビスコ セラピューティクス カンパニー リミテッド Ｆｇｆｒ４阻害剤酸性塩およびその製造方法と使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201439064A (zh) * 2013-03-15 2014-10-16 Hutchison Medipharma Ltd 新型嘧啶和吡啶類化合物及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
KR102548229B1 (ko) * 2015-04-14 2023-06-27 에자이 알앤드디 매니지먼트 가부시키가이샤 결정질 fgfr4 억제제 화합물 및 그의 용도
WO2018099451A1 (zh) 2016-12-01 2018-06-07 和记黄埔医药（上海）有限公司 化合物的晶型

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201439064A (zh) * 2013-03-15 2014-10-16 Hutchison Medipharma Ltd 新型嘧啶和吡啶類化合物及其用途

Also Published As

Publication number Publication date
CN114555558A (zh) 2022-05-27
US20230121346A1 (en) 2023-04-20
UA129777C2 (uk) 2025-07-30
AU2020367905A1 (en) 2022-04-21
EP4045484A1 (en) 2022-08-24
IL292206B2 (en) 2026-03-01
CN114555558B (zh) 2024-12-17
US12559472B2 (en) 2026-02-24
TW202128669A (zh) 2021-08-01
AR120202A1 (es) 2022-02-02
EP4045484A4 (en) 2023-09-06
CN119462616A (zh) 2025-02-18
MX2022004274A (es) 2022-05-06
WO2021073494A1 (en) 2021-04-22
CA3154064A1 (en) 2021-04-22
JP2025143319A (ja) 2025-10-01
KR20220088712A (ko) 2022-06-28
IL292206A (en) 2022-06-01
JP2022552329A (ja) 2022-12-15
IL292206B1 (en) 2025-11-01
CN119751422A (zh) 2025-04-04
BR112022007035A2 (pt) 2022-06-28

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
CN105452250B (zh) 5,10‑亚甲基‑(6r)‑四氢叶酸的半硫酸盐
CN106604919B (zh) 6-((6,7-二甲氧基喹唑啉-4-基)氧基)-n,2-二甲基苯并呋喃-3-甲酰胺晶型
CN106459091A (zh) C‑Met抑制剂结晶型游离碱或其结晶型酸式盐及其制备方法和应用
JP2025143319A (ja) 化合物の塩及びその結晶形態
HK40122795A (zh) 化合物的盐及其晶型
HK40068973B (zh) 化合物的盐及其晶型
HK40120202A (zh) 化合物的盐及其晶型
HK40068973A (en) The salts of a compound and the crystalline forms thereof
WO2020011141A1 (zh) 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
WO2026026904A1 (en) The crystalline forms of a compound
TWI867817B (zh) 一種二噁烷並喹啉類化合物的鹽、其晶型以及它們的製備方法及用途
WO2018099451A1 (zh) 化合物的晶型
EA046831B1 (ru) Соли соединения и их кристаллические формы
WO2023230968A1 (zh) Shp2抑制剂、其晶型及其制备方法与用途
WO2026046946A1 (en) New solid forms of (3r)-n-[2-cyano-4-fluoro-3-(3-methyl-4-oxo-quinazolin-6-yl)oxy-phenyl]-3-fluoro-pyrrolidine-1-sulfonamide
WO2022247772A1 (zh) 一种含氧杂环化合物的晶型、其制备方法及应用
HK40024929B (en) Crystalline forms of a compound
HK40024929A (en) Crystalline forms of a compound
WO2020043078A1 (zh) 新型氮杂三环类化合物的盐型、晶型及其用途
HK40042843A (en) Salt form and crystal form of novel azatricyclic compound and use thereof
HK1231479B (zh) 6-((6，7-二甲氧基喹唑啉-4-基)氧基)-n，2-二甲基苯并呋喃-3-甲酰胺晶型